Irish data on the safety and efficacy of vedolizumab in the treatment of inflammatory bowel disease

References

• Rieder F, Zimmermann EM, Remzi FH, et al. Crohn’s disease complicated by strictures: a systematic review. Gut. 2013;62:1072–1084.
   PubMed Web of Science ®Google Scholar
• Sabino J, Verstockt B, Vermeire S, et al. New biologics and small molecules in inflammatory bowel disease: an update. Ther Adv Gastroenterol [Internet]. 2019 May 26 [cited 2020 Jan 30];12. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537282/
   PubMed Web of Science ®Google Scholar
• Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384–413.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013;369:754–762.
   PubMed Web of Science ®Google Scholar
• Farrell RJ. Biologics beyond anti-TNF agents for ulcerative colitis - efficacy, safety, and cost? N Engl J Med. 2019;381:1279–1281.
   PubMed Web of Science ®Google Scholar
• Argollo M, Fiorino G, Hindryckx P, et al. Novel therapeutic targets for inflammatory bowel disease. J Autoimmun. 2017;85:103–116.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721.
   PubMed Web of Science ®Google Scholar
• Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147:618–627.e3.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Singh S, Jiang X, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe crohn’s disease: results from the US VICTORY consortium. Am J Gastroenterol. 2016;111:1147–1155.
   PubMed Web of Science ®Google Scholar
• Narula N, Peerani F, Meserve J, et al. Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018;113:1345.
   PubMed Web of Science ®Google Scholar
• Magro F, Gionchetti P, Eliakim R, et al.; European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649–670.
   PubMed Web of Science ®Google Scholar
• Gomollón F, Dignass A, Annese V, et al.; ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017;11:3–25.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–1666.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn’s disease activity and Harvey–Bradshaw indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol. 2010;8:357–363.
   PubMed Web of Science ®Google Scholar
• Ylisaukko-Oja T, Aaltonen J, Nuutinen H, et al. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab – a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO). Scand J Gastroenterol. 2018;53:158–167.
   PubMed Web of Science ®Google Scholar
• Amiot A, Serrero M, Peyrin-Biroulet L, et al.; OBSERV-IBD study group and the GETAID. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46:310–321.
   PubMed Web of Science ®Google Scholar
• Shelton E, Allegretti JR, Stevens B, et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort. Inflamm Bowel Dis. 2015;21:2879–2885.
   PubMed Web of Science ®Google Scholar
• Eriksson C, Marsal J, Bergemalm D, et al.; The SWIBREG Vedolizumab Study Group. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scand J Gastroenterol. 2017;52:722–729.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Schwartz D, Danese S, et al. Efficacy of vedolizumab in fistulising Crohn’s disease: exploratory analyses of data from GEMINI 2. J Crohns Colitis. 2018;12:621–626.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Jones GR, Plevris N, et al. Association Between Level of Fecal Calprotectin and Progression of Crohn’s Disease. Clin Gastroenterol Hepatol. 2019;17:2269–2276.e4.
   PubMed Web of Science ®Google Scholar
• Singh S, Fumery M, Sandborn WJ, et al. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47:162–175.
   PubMed Web of Science ®Google Scholar
• Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med. 2019;381(13):1215–1226.
   Google Scholar
• Adar T, Faleck D, Sasidharan S, et al. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther. 2019;49:873–879.
   PubMed Web of Science ®Google Scholar
• Patel H, Latremouille-Viau D, Burne R, et al. Comparison of real-world treatment outcomes with vedolizumab versus infliximab in biologic-naive patients with inflammatory bowel disease. Crohns Colitis 360. 2019 [cited 2020 Feb 1];1:otz022. Available from: https://academic.oup.com/crohnscolitis360/article/1/2/otz022/5545355
   Google Scholar
• Scott FI, Luo M, Shah Y, et al. Identification of the most cost-effective position of vedolizumab among the available biologic drugs for the treatment of ulcerative colitis. J Crohns Colitis. 2020 [cited Apr 20]. Available from: https://academic.oup.com/ecco-jcc/advance-article/doi/10.1093/ecco-jcc/jjz212/5696657
   PubMedGoogle Scholar
• Schneider Y, Saumoy M, Cohen-Mekelburg S, et al. The cost-effectiveness of vedolizumab for inflammatory bowel disease: a review of the current literature. Gastroenterol Hepatol (N Y). 2016;12:617–621.
   PubMedGoogle Scholar
• Sandborn WJ, Baert F, Danese S, et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158:562–572.e12.
   PubMed Web of Science ®Google Scholar
• Cohen RD, Bhayat F, Blake A, et al. The safety profile of vedolizumab in ulcerative colitis and Crohn’s disease: 4 years of global post-marketing data. J Crohns Colitis. 2020;14:192–204.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Garre A, Ricart E, et al.; GETECCU study group. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. Aliment Pharmacol Ther. 2018;48:839–851.
   PubMed Web of Science ®Google Scholar
• Stallmach A, Langbein C, Atreya R, et al. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. Aliment Pharmacol Ther. 2016;44:1199–1212.
   PubMed Web of Science ®Google Scholar